Mangoceuticals (MGRX) Competitors

$0.39 +0.05 (+15.62%)

Closing price 04:00 PM Eastern

Extended Trading

$0.40 +0.00 (+0.74%)

As of 07:53 PM Eastern

MGRX vs. PIII, CCM, BMGL, ADVB, and ACON

Should you buy Mangoceuticals stock or one of its competitors? MarketBeat compares Mangoceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Mangoceuticals include P3 Health Partners (PIII), Concord Medical Services (CCM), Basel Medical Group (BMGL), Advanced Biomed (ADVB), and Aclarion (ACON). These companies are all part of the "healthcare" industry.

How does Mangoceuticals compare to P3 Health Partners?

Mangoceuticals (NASDAQ:MGRX) and P3 Health Partners (NASDAQ:PIII) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

P3 Health Partners has a net margin of -10.14% compared to Mangoceuticals' net margin of -4,536.70%. Mangoceuticals' return on equity of -109.38% beat P3 Health Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mangoceuticals	-4,536.70%	-109.38%	-102.40%
P3 Health Partners	-10.14%	-302.33%	-20.72%

Mangoceuticals has a beta of 2.12, suggesting that its share price is 112% more volatile than the broader market. Comparatively, P3 Health Partners has a beta of 0.48, suggesting that its share price is 52% less volatile than the broader market.

In the previous week, P3 Health Partners had 1 more articles in the media than Mangoceuticals. MarketBeat recorded 3 mentions for P3 Health Partners and 2 mentions for Mangoceuticals. Mangoceuticals' average media sentiment score of 1.43 beat P3 Health Partners' score of 0.93 indicating that Mangoceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Mangoceuticals	Positive
P3 Health Partners	Positive

56.7% of Mangoceuticals shares are owned by institutional investors. Comparatively, 7.8% of P3 Health Partners shares are owned by institutional investors. 16.0% of Mangoceuticals shares are owned by insiders. Comparatively, 17.8% of P3 Health Partners shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

P3 Health Partners has a consensus price target of $3.50, indicating a potential downside of 13.15%. Given P3 Health Partners' stronger consensus rating and higher probable upside, analysts clearly believe P3 Health Partners is more favorable than Mangoceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mangoceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
P3 Health Partners	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Mangoceuticals has higher earnings, but lower revenue than P3 Health Partners. Mangoceuticals is trading at a lower price-to-earnings ratio than P3 Health Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mangoceuticals	$460K	14.50	-$20.64M	-$2.56	N/A
P3 Health Partners	$1.46B	0.02	-$147.95M	-$45.20	N/A

Summary

P3 Health Partners beats Mangoceuticals on 9 of the 16 factors compared between the two stocks.

How does Mangoceuticals compare to Concord Medical Services?

Mangoceuticals (NASDAQ:MGRX) and Concord Medical Services (NYSE:CCM) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability.

Concord Medical Services has a net margin of 0.00% compared to Mangoceuticals' net margin of -4,536.70%. Concord Medical Services' return on equity of 0.00% beat Mangoceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mangoceuticals	-4,536.70%	-109.38%	-102.40%
Concord Medical Services	N/A	N/A	N/A

56.7% of Mangoceuticals shares are owned by institutional investors. 16.0% of Mangoceuticals shares are owned by insiders. Comparatively, 46.5% of Concord Medical Services shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Concord Medical Services has higher revenue and earnings than Mangoceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mangoceuticals	$460K	14.50	-$20.64M	-$2.56	N/A
Concord Medical Services	$65.85M	0.33	-$13.27M	N/A	N/A

Mangoceuticals has a beta of 2.12, suggesting that its stock price is 112% more volatile than the broader market. Comparatively, Concord Medical Services has a beta of -1.09, suggesting that its stock price is 209% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mangoceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Concord Medical Services	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Mangoceuticals had 1 more articles in the media than Concord Medical Services. MarketBeat recorded 2 mentions for Mangoceuticals and 1 mentions for Concord Medical Services. Mangoceuticals' average media sentiment score of 1.43 beat Concord Medical Services' score of 0.75 indicating that Mangoceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Mangoceuticals	Positive
Concord Medical Services	Positive

Summary

Concord Medical Services beats Mangoceuticals on 6 of the 11 factors compared between the two stocks.

How does Mangoceuticals compare to Basel Medical Group?

Basel Medical Group (NASDAQ:BMGL) and Mangoceuticals (NASDAQ:MGRX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

56.7% of Mangoceuticals shares are held by institutional investors. 16.0% of Mangoceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Basel Medical Group has a net margin of 0.00% compared to Mangoceuticals' net margin of -4,536.70%. Basel Medical Group's return on equity of 0.00% beat Mangoceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Basel Medical Group	N/A	N/A	N/A
Mangoceuticals	-4,536.70%	-109.38%	-102.40%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Basel Medical Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mangoceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Basel Medical Group has higher revenue and earnings than Mangoceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Basel Medical Group	$8.90M	1.48	-$9.50M	N/A	N/A
Mangoceuticals	$460K	14.50	-$20.64M	-$2.56	N/A

Basel Medical Group has a beta of 0.07, indicating that its stock price is 93% less volatile than the broader market. Comparatively, Mangoceuticals has a beta of 2.12, indicating that its stock price is 112% more volatile than the broader market.

In the previous week, Basel Medical Group and Basel Medical Group both had 2 articles in the media. Mangoceuticals' average media sentiment score of 1.43 beat Basel Medical Group's score of 1.31 indicating that Mangoceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Basel Medical Group	Positive
Mangoceuticals	Positive

Summary

Basel Medical Group and Mangoceuticals tied by winning 5 of the 10 factors compared between the two stocks.

How does Mangoceuticals compare to Advanced Biomed?

Advanced Biomed (NASDAQ:ADVB) and Mangoceuticals (NASDAQ:MGRX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

56.7% of Mangoceuticals shares are owned by institutional investors. 34.4% of Advanced Biomed shares are owned by company insiders. Comparatively, 16.0% of Mangoceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Advanced Biomed	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mangoceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Advanced Biomed and Advanced Biomed both had 2 articles in the media. Mangoceuticals' average media sentiment score of 1.43 beat Advanced Biomed's score of 1.21 indicating that Mangoceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Advanced Biomed	Positive
Mangoceuticals	Positive

Advanced Biomed has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market. Comparatively, Mangoceuticals has a beta of 2.12, suggesting that its stock price is 112% more volatile than the broader market.

Advanced Biomed has a net margin of 0.00% compared to Mangoceuticals' net margin of -4,536.70%. Advanced Biomed's return on equity of 92.11% beat Mangoceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Advanced Biomed	N/A	92.11%	58.03%
Mangoceuticals	-4,536.70%	-109.38%	-102.40%

Advanced Biomed has higher earnings, but lower revenue than Mangoceuticals. Mangoceuticals is trading at a lower price-to-earnings ratio than Advanced Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Advanced Biomed	N/A	N/A	-$3.26M	$3.80	1.17
Mangoceuticals	$460K	14.50	-$20.64M	-$2.56	N/A

Summary

Advanced Biomed beats Mangoceuticals on 7 of the 11 factors compared between the two stocks.

How does Mangoceuticals compare to Aclarion?

Aclarion (NASDAQ:ACON) and Mangoceuticals (NASDAQ:MGRX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations.

Mangoceuticals has a net margin of -4,536.70% compared to Aclarion's net margin of -10,320.51%. Aclarion's return on equity of -61.10% beat Mangoceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclarion	-10,320.51%	-61.10%	-58.01%
Mangoceuticals	-4,536.70%	-109.38%	-102.40%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclarion	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mangoceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Aclarion had 7 more articles in the media than Mangoceuticals. MarketBeat recorded 9 mentions for Aclarion and 2 mentions for Mangoceuticals. Mangoceuticals' average media sentiment score of 1.43 beat Aclarion's score of 1.05 indicating that Mangoceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Aclarion	Positive
Mangoceuticals	Positive

Aclarion has higher earnings, but lower revenue than Mangoceuticals. Aclarion is trading at a lower price-to-earnings ratio than Mangoceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclarion	$80K	99.02	-$7.23M	-$17.01	N/A
Mangoceuticals	$460K	14.50	-$20.64M	-$2.56	N/A

Aclarion has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market. Comparatively, Mangoceuticals has a beta of 2.12, suggesting that its stock price is 112% more volatile than the broader market.

7.5% of Aclarion shares are owned by institutional investors. Comparatively, 56.7% of Mangoceuticals shares are owned by institutional investors. 0.8% of Aclarion shares are owned by company insiders. Comparatively, 16.0% of Mangoceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Mangoceuticals beats Aclarion on 8 of the 13 factors compared between the two stocks.

Get Mangoceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MGRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MGRX vs. The Competition

Export

Metric	Mangoceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.77M	$3.06B	$6.34B	$12.38B
Dividend Yield	N/A	1.96%	2.80%	5.35%
P/E Ratio	-0.15	18.70	20.90	25.61
Price / Sales	14.50	272.77	549.47	78.77
Price / Cash	N/A	57.78	43.26	56.33
Price / Book	0.42	4.42	9.93	6.96
Net Income	-$20.64M	$72.19M	$3.55B	$333.52M
7 Day Performance	15.58%	-0.62%	-0.33%	0.45%
1 Month Performance	1.31%	0.22%	1.34%	4.06%
1 Year Performance	-74.88%	46.24%	41.10%	36.24%

Mangoceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MGRX Mangoceuticals	1.3878 of 5 stars	$0.39 +15.6%	N/A	-79.3%	$5.77M	$460K	N/A	3	Positive News Short Interest Decrease
PIII P3 Health Partners	1.0764 of 5 stars	$3.51 -1.8%	$3.50 -0.4%	-56.4%	$24.79M	$1.46B	N/A	500	News Coverage Gap Up
CCM Concord Medical Services	0.732 of 5 stars	$5.21 +1.3%	N/A	-40.6%	$22.62M	$460.51M	N/A	970
BMGL Basel Medical Group	0.5872 of 5 stars	$0.71 -7.2%	N/A	-83.4%	$13.23M	$8.90M	N/A	36
ADVB Advanced Biomed	1.2552 of 5 stars	$7.10 -1.4%	N/A	N/A	$9.69M	N/A	1.87	40	Positive News Short Interest Decrease Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MGRX) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mangoceuticals (MGRX) Competitors

MGRX vs. PIII, CCM, BMGL, ADVB, and ACON

How does Mangoceuticals compare to P3 Health Partners?

Summary

How does Mangoceuticals compare to Concord Medical Services?

Summary

How does Mangoceuticals compare to Basel Medical Group?

Summary

How does Mangoceuticals compare to Advanced Biomed?

Summary

How does Mangoceuticals compare to Aclarion?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGRX vs. The Competition

Mangoceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mangoceuticals (MGRX) Competitors

MGRX vs. PIII, CCM, BMGL, ADVB, and ACON

How does Mangoceuticals compare to P3 Health Partners?

Is MGRX or PIII more profitable?

Which has more volatility & risk, MGRX or PIII?

Does the media refer more to MGRX or PIII?

Do insiders and institutionals believe in MGRX or PIII?

Do analysts recommend MGRX or PIII?

Which has better valuation & earnings, MGRX or PIII?

Summary

How does Mangoceuticals compare to Concord Medical Services?

Is MGRX or CCM more profitable?

Do institutionals and insiders have more ownership in MGRX or CCM?

Which has preferable valuation and earnings, MGRX or CCM?

Which has more risk & volatility, MGRX or CCM?

Do analysts prefer MGRX or CCM?

Does the media prefer MGRX or CCM?

Summary

How does Mangoceuticals compare to Basel Medical Group?

Do institutionals and insiders hold more shares of BMGL or MGRX?

Is BMGL or MGRX more profitable?

Do analysts recommend BMGL or MGRX?

Which has preferable earnings & valuation, BMGL or MGRX?

Which has more risk & volatility, BMGL or MGRX?

Does the media favor BMGL or MGRX?

Summary

How does Mangoceuticals compare to Advanced Biomed?

Do institutionals and insiders believe in ADVB or MGRX?

Do analysts recommend ADVB or MGRX?

Does the media prefer ADVB or MGRX?

Which has more volatility & risk, ADVB or MGRX?

Is ADVB or MGRX more profitable?

Which has better valuation and earnings, ADVB or MGRX?

Summary

How does Mangoceuticals compare to Aclarion?

Is ACON or MGRX more profitable?

Do analysts recommend ACON or MGRX?

Does the media prefer ACON or MGRX?

Which has preferable valuation and earnings, ACON or MGRX?

Which has more risk and volatility, ACON or MGRX?

Do institutionals and insiders have more ownership in ACON or MGRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGRX vs. The Competition

Mangoceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools